Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Medtronic reports TTOP-AF trial results

Medtronic has reported the results of its tailored treatment of permanent atrial fibrillation (TTOP-AF) trial.

The controlled, multi-center, prospective, randomized trial included a total of 210 patients with persistent and long-standing persistent AF received either Medtronic’s Phased radio frequency (RF) Ablation System ablation treatment (138) or traditional medical management (72).

The data showed that 55.8 % of ablation management patients had an AF and atrial flutter burden reduction of greater than 90 % and were free of antiarrhythmic drug therapy at six months compared to 26.4 % in the traditional medical management arm (p<0.0001), thus meeting the chronic effectiveness endpoint.

Medtronic’s Ablation system incorporates a percutaneous cardiac catheter and generator system that delivers customized RF energy designed to eliminate or isolate abnormal electrical impulses in the left atrium that initiate or sustain atrial fibrillation.